SLC5A2 and diabetic kidney disease: Large-scale clinical trials among patients with type 2 diabetes revealed that SGLT2 inhibitors prevented macrovascular events such as myocardial infarction, stroke, and heart failure [2,3] and also prevented diabetic kidney diseases such as DN [4].